80 CENTS PRICE TARGET, page-171

There has been recent talk about the IRX-211 inhaler and why no body has seen it. Not even a picture of the delivery method used for this drug.

So looking further into this-

---
Manufacturing Booked In: The first drawdown under the Clendon Capital facility—$247,500—has
already been effected to secure batch manufacturing and stability testing of IRX-211 with Ab Initio Pharma, a GMP-accredited partner based in Sydney, Australia.

https://www.marketindex.com.au/asx/...-for-redesigned-irx211-phase-2-trial-3A669321
---

Who are Ab Initio Pharma...  ?
https://ab-initio-pharma.com

Very interesting to discover on their LinkedIn page some very recent posts about Professor Daniela Traini and her work around the development of soft-mist inhalers. Could her work dovetail with the delivery of IRX-211? I know IRX has an inhaler... but could the work done by Dr Traini possibly help as IRX enters phase II, or is the inhaler used in Phase 1 the one they will need to use for Phase II?

Some reading for those that want to know more:

https://ab-initio-pharma.com/news/2...e-daniela-traini-to-keynote-at-smilondon-2025

https://www.linkedin.com/posts/ab-initio-pharma_smi2025-activity-7343567517786730497-hQCK